BlackRock et al. back Immunocore in $75m series-C

The company will use the proceeds to further expand and accelerate its growing clinical-stage pipeline of ImmTAX.

The funding comes after positive phase-III clinical trial data of the company's lead drug tebentafusp. 

The company has also secured a $100m senior secured loan facility from Oxford Finance, and plans to use the funding for general corporate purposes, as well as to fund a potential commercial launch of tebentafusp.

Previous funding
In 2012, Immunocore received a £2.4m grant from Biomedical Catalyst Fund. Three years later, Woodford Investment Management, RTW Investments and Eli Lilly invested $320m in a series-A round. 

In March 2020, Immunocore raised $130m in series-B financing led by General Atlantic, with participation from CCB International, JDRF T1D Fund, Rock Springs Capital, Terra Magnum Capital Partners and WuXi AppTec's Corporate Venture Fund, Eli Lilly and Company, and RTW Investments, among others.

Company
Founded in 2008 and based in Abingdon, Immunocore is a late-stage biotechnology company developing a new class of T cell receptor (TCR) bispecific immunotherapies to treat a broad range of diseases, including cancer, infectious and autoimmune disease.

The company has around 300 staff, according to its LinkedIn page. 

People
Immunocore – Bahija Jallal (CEO)

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• BlackRock
• General Atlantic
• United Kingdom
• Venture